Quick Answer
Aprea Therapeutics, Inc. reported Operating Income Loss of -$13.23 million for the year ending 2025.
- Aprea Therapeutics, Inc. showed an increase of +7.6% in Operating Income Loss from 2024 to 2025.
- This data is from Aprea Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: -$98.47 million | Q3 2022: -$4.20 million | Q1 2023: -$4.62 million | Q2 2023: -$3.65 million | Q3 2023: -$3.52 million | Q1 2024: -$3.15 million | Q2 2024: -$3.85 million | Q3 2024: -$4.10 million | Q1 2025: -$4.09 million | Q2 2025: -$3.39 million | Q3 2025: -$3.12 million.
- Over the full 5 years of available data (2021 to 2025), Aprea Therapeutics, Inc.'s Operating Income Loss has grown by 64.7%.
- Historical annual values: Fiscal year 2025: -$13.23 million | Fiscal year 2024: -$14.32 million | Fiscal year 2023: -$15.47 million | Fiscal year 2022: -$113.39 million | Fiscal year 2021: -$37.45 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: